April 2021 Simoa® Publications:
Neurology: Alzheimer’s Disease and Parkinson’s Disease
Plasma P-tau181 to Aβ42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer’s disease patients with concomitant cerebrovascular disease
Chong JR, et al.
Alzheimer’s & Dementia : The Journal of the Alzheimer’s Association. 2021
Alzheimer’s Disease
Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer’s disease
Tissot C, et al.
Alzheimers Res Ther. 2021;13:69
Alzheimer’s Disease
Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia
Wang C, et al.
Neuron. 2021
Alzheimer’s Disease
Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals
Lussier FZ, et al.
Brain Communications. 2021
Alzheimer’s Disease
Physiological clearance of amyloid-beta by the kidney and its therapeutic potential for Alzheimer’s disease
Tian DY, et al.
Molecular Psychiatry. 2021
Alzheimer’s Disease
Elevated plasma neurofilament light predicts a faster rate of cognitive decline over 5 years in participants with objectively-defined subtle cognitive decline and MCI
Bangen KJ, et al.
Alzheimer’s & Dementia : The Journal of the Alzheimer’s Association. 2021
Alzheimer’s Disease
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
Swanson CJ, et al.
Alzheimers Res Ther. 2021;13:80
Alzheimer’s Disease
Amyloid related cerebral microbleed and plasma Aβ40 are associated with cognitive decline in Parkinson’s disease
Tsai HH, et al.
Sci Rep. 2021;11:7115
Parkinson’s Disease
April 2021 Simoa® Publications in Other Therapeutic Areas
